PMID-38873891 – Long-term Teduglutide in Pediatric SBS
Wales PW, Chiba M, Masumoto K, Nagelkerke SCJ, et al. Long-term Outcomes of Teduglutide in Pediatric Patients With Short Bowel Syndrome-Associated Intestinal Failure: A Pooled Post Hoc Analysis. J Pediatr Gastroenterol Nutr. 2024;79(1):94-103.
Quick Reference
| Property | Value |
|---|---|
| PMID | 38873891 |
| DOI | 10.1002/jpn3.12276 |
| Year | 2024 |
| Journal | Journal of Pediatric Gastroenterology and Nutrition |
| Study Type | Pooled Post Hoc Analysis |
| Evidence Level | III |
| Sample | n=85 pediatric patients pooled from Phase III trials and extensions (up to 96 weeks) |
| Peptide(s) Studied | GLP-2 |
Key Findings
- Pooled analysis of 85 children with SBS-IF treated with teduglutide 0.05 mg/kg/day for up to 96 weeks across multiple studies
- 82.1% of patients achieved a clinical response (>=20% reduction in parenteral support) over the pooled observation period
- Mean parenteral fluid volume decreased by 30.1 mL/kg/day from baseline, representing a substantial reduction in IV dependence
- Parenteral support reductions were durable and progressive through 96 weeks, without evidence of a treatment plateau
- Several patients achieved enteral autonomy during the extended treatment period, confirming the potential for curative-intent therapy
- Long-term safety was consistent with the known profile; no new safety signals emerged with extended exposure; growth remained on trajectory
Study Design
Pooled post hoc analysis combining data from two Phase III pediatric teduglutide studies and their open-label extension studies. Included all pediatric patients (aged 1-17 years) who received at least one dose of teduglutide. Assessed efficacy (parenteral support reduction, clinical response rate, enteral autonomy) and safety outcomes over up to 96 weeks of continuous treatment.
Limitations
- Post hoc pooled analysis, not a prospectively designed long-term study; inherent selection bias as patients who discontinued early are underrepresented in later time points
- Open-label design for extension period introduces observer bias
- No concurrent placebo comparator for the long-term data, making it difficult to fully attribute outcomes to treatment vs natural adaptation
- Heterogeneous patient population (varying ages, etiologies, remnant anatomy) limits ability to identify predictors of response
Clinical Relevance
This is the most comprehensive long-term pediatric teduglutide dataset published to date. The 82.1% response rate and sustained reductions over 96 weeks confirm that GLP-2 receptor agonism produces durable intestinal adaptation in children, not merely a transient effect. The progressive nature of the benefit supports extended treatment courses. For the GLP-2 peptide profile, this study provides the strongest evidence that long-term teduglutide therapy can meaningfully reduce or eliminate parenteral nutrition dependence in pediatric SBS-IF.
Related
#research #observational #glp-2 #evidence-level-III